Láng I, Nékám K, González-Cabello R, Mũzes G, Gergely P, Fehér J
Second Department of Medicine, Semmelweis University Medical School, Budapest, Hungary.
Tokai J Exp Clin Med. 1990 May;15(2-3):123-7.
The hepatoprotective and immunomodulatory effects of silymarin and amino-imidazole-carboxamide-phosphate were studied in 40 patients with alcoholic cirrhosis of the liver in a one-month double-blind clinical trial. Treatment with either of the drugs normalized the elevated levels of aspartate aminotransferase, alanine aminotransferase and serum bilirubin, markedly reduced the high level of gamma-glutamyl transferase, increased lectin-induced lymphoblast transformation, decreased the percentage of OKT8+ cells and suppressed lymphocytotoxicity. None of these changes occurred in the placebo-treated group. Thus, the hepatoprotective effects of silymarin and amino-imidazole-carboxamide-phosphate in alcoholic cirrhosis can partly be attributed to the immunomodulatory activity of the drugs.
在一项为期一个月的双盲临床试验中，对40例酒精性肝硬化患者研究了水飞蓟素和氨基咪唑甲酰胺磷酸盐的肝脏保护和免疫调节作用。使用这两种药物中的任何一种进行治疗，均可使升高的天冬氨酸转氨酶、丙氨酸转氨酶和血清胆红素水平恢复正常，显著降低高水平的γ-谷氨酰转移酶，增加凝集素诱导的淋巴细胞母细胞转化，降低OKT8+细胞百分比并抑制淋巴细胞毒性。在安慰剂治疗组中未出现这些变化。因此，水飞蓟素和氨基咪唑甲酰胺磷酸盐在酒精性肝硬化中的肝脏保护作用部分可归因于药物的免疫调节活性。
